Lauren Ling

Ms. Lauren Ling

Tufts University, Medford, Massachusetts, USA
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ABAsma Boukhalfa
Asma Boukhalfa
SRSally Robinson
Sally Robinson
DMDawn M Meola
Dawn M Meola
NRNicholas A Robinson
Nicholas A Robinson
LLLauren Ling
Lauren Ling
Vicky YangVicky Yang
Vicky Yang
Chemotherapy-induced impairment of autophagy is implicated in cardiac toxicity induced by anti-cancer drugs. Imperfect translation from rodent models and lack of in vitro models of toxicity has limited investigation of autophagic flux dysregulation, preventing design of novel cardioprotective strategies based on autophagy control. Development of an adult heart tissue culture technique from a translational model will improve investigation of cardiac toxicity. We aimed to optimize a canine cardiac slice culture system for exploration of cancer therapy impact on intact cardiac tissue, creating a translatable model that maintains autophagy in culture and is amenable to autophagy modulation. Canine cardiac tissue slices (350 μm) were generated from left ventricular free wall collected from euthanized client-owned dogs (n = 7) free of cardiovascular disease at the Foster Hospital for Small Animals at Tufts University. Cell viability and apoptosis were quantified with MTT assay and TUNEL staining. Cardiac slices were challenged with doxorubicin and an autophagy activator (rapamycin) or inhibitor (chloroquine). Autophagic flux components (LC3, p62) were quantified by western blot. Cardiac slices retained high cell viability for >7 days in culture and basal levels of autophagic markers remained unchanged. Doxorubicin treatment resulted in perturbation of the autophagic flux and cell death, while rapamycin co-treatment restored normal autophagic flux and maintained cell survival. We developed an adult canine cardiac slice culture system appropriate for studying the effects of autophagic flux that may be applicable to drug toxicity evaluations.

30 April 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
LPLakshmi Pulakat
Lakshmi Pulakat
Howard H ChenHoward H Chen
Howard H Chen
MGMadhavi P. Gavini
Madhavi P. Gavini
LLLauren Ling
Lauren Ling
YTYinian Tang
Yinian Tang
HSHongmin Sun
Hongmin Sun
Wound infection by multidrug-resistant (MDR) bacteria is a major disease burden. Systemic administration of broad-spectrum antibiotics colistin methanesulfonate (CMS) and vancomycin are the last lines of defense against deep wound infections by MDR bacteria. However, systemic administration of CMS and vancomycin are linked to life-threatening vital organ damage. Currently there are no effective topical application strategies to deliver these high molecular weight antibiotics across the stratum corneum. To overcome this difficulty, we tested if high molecular weight antibiotics delivered by Droplette micromist technology device (DMTD), a transdermal delivery device that generates a micromist capable of packaging large molecules, could attenuate deep skin tissue infections. Using green fluorescent protein-tagged E. coli and live tissue imaging, we show that (1) the extent of attenuation of deep-skin E. coli infection was similar when treated with topical DMTD- or systemic IP (intraperitoneal)-delivered CMS; (2) DMTD-delivered micromist did not spread the infection deeper; (3) topical DMTD delivery and IP delivery resulted in similar levels of vancomycin in the skin after a 2 h washout period; and (4) IP-delivered vancomycin was about 1000-fold higher in kidney and plasma than DMTD-delivered vancomycin indicating systemic toxicity. Thus, topical DMTD delivery of these antibiotics is a safe treatment for the difficult-to-treat deep skin tissue infections by MDR bacteria.

1 May 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
LLLauren Ling
Lauren Ling
Asma BoukhalfaAsma Boukhalfa
Asma Boukhalfa
AKAndrew H. Kung
Andrew H. Kung
Vicky YangVicky Yang
Vicky Yang
Howard H ChenHoward H Chen
Howard H Chen
Autophagy, an evolutionarily conserved process, plays an important role in cellular homeostasis and human diseases. Cardiovascular dysfunction, which presents during cancer treatment or in cancer-free individuals years after treatment, is a growing clinical challenge. Millions of cancer survivors and patients face an unpredictable risk of developing cardiotoxicity. Cardiotoxicity due to cancer treatment, as well as cancer progression, has been linked to autophagy dysregulation. Modulating autophagy has been further proposed as a therapeutic treatment for both cancer and cardiovascular disorders. The safe and effective use of autophagy modulation as a cardioprotective strategy during cancer treatment especially requires careful consideration and experimentation to minimize the impact on cancer treatment. We focus here on recent advances in targeted autophagy modulation strategies that utilize interdisciplinary approaches in biomedical sciences and are potentially translatable to treat cardiotoxicity and improve cancer treatment outcomes. This review highlights non-small molecule autophagy modulators to enhance targeted therapy, nanomedicine for autophagy modulation and monitoring, and in vitro models and future experiments needed to bring novel autophagy discoveries from basic research to clinical translation.

1 August 2025 in Radiology
Verified
Journal Article
Closed access
JRJavier M. Romero
Javier M. Romero
JBJames A. Brink
James A. Brink
SJSai Dhanush Reddy Jeggari
Sai Dhanush Reddy Jeggari
LLLauren Ling
Lauren Ling
TPTheodore Thomas Pierce
Theodore Thomas Pierce
ASAnthony E. Samir
Anthony E. Samir
This article aims to create a framework for comprehensive, standardized point-of-care US practice across a health care system; this framework requires policies and guidelines like those of other clinical imaging programs.

24 September 2025 in Radiology Advances
Verified
Journal Article
Open access
TPTheodore Thomas Pierce
Theodore Thomas Pierce
KNKim Naja
Kim Naja
SSScott J Schoen
Scott J Schoen
RTRimon Tadross
Rimon Tadross
MWMichael H Wang
Michael H Wang
ASAnthony E. Samir
Anthony E. Samir
Background: Metabolic dysfunction-associated steatotic liver disease affects 1 in 3 people worldwide. Ultrasound shear wave elastography (SWE) in obese patients, the target population for testing, is hampered by beam attenuation, leading to unreliable liver fibrosis quantification. Purpose: We assess the safety and efficacy of increased push mechanical index (IPMI) above U.S. Food and Drug Administration limits to improve SWE. Materials and methods: This single-center prospective trial (July 2023-April 2024) (NCT05792423) enrolled healthy adults stratified by body mass index (BMI). Participants underwent conventional push pulse (mechanical index [MI] 1.4) and IPMI (MI 2.5) SWE (GE Healthcare LOGIQ E10) performed by 1 of 3 sonographers and serial liver function testing (LFT) before and up to 7 days after imaging. Liver injury was defined as increased serum alanine transaminase (ALT), aspartate aminotransferase (AST), or alkaline phosphatase (ALP) (non-inferiority margins: AST 7.5 U/L, ALT 12 U/L, ALP 17.5 U/L). Secondary endpoints included SWE variability and measurement number. Results: Twenty-two analyzable participants (mean age 39.6 ± 16.3 years; 15 women) had normal BMI (6), overweight (6), class 1 obesity (7), and class 2 obesity (3). Conventional shear wave speed was 1.34 ± 0.21 m/s, and IPMI yielded 1.36 ± 0.20 m/s (velocities ≤ 1.34 m/s indicate minimal or no fibrosis). The mean [95% CI] LFT change from baseline to day 1 was 1) AST: −0.86 [−2.34, 0.61], P = .24, 2) ALT: 0.32 [−1.04, 1.68], P = .63, 3) ALP: 1.73 [−1.02, 4.47], P = .21. The upper 95% CI for all biomarkers met non-inferiority criteria. Mean IPMI interquartile range (IQR) to median ratio decreased 0.019 (29.2% relative reduction) (P = .01) with 0.68 [IQR: 0.0.75] (P = .058), fewer average attempts. Conclusion: IPMI SWE in healthy volunteers did not cause injury and reduced measurement variability. IPMI SWE should be developed to improve examination quality and reliability in obese patients.

4 November 2024 in WFUMB Ultrasound Open
Verified
Journal Article
Open access
SJSai Dhanush Reddy Jeggari
Sai Dhanush Reddy Jeggari
LLLauren Ling
Lauren Ling
KPKathleen R. Pope
Kathleen R. Pope
ASAnthony E. Samir
Anthony E. Samir
TPTheodore Thomas Pierce
Theodore Thomas Pierce